Veeva Sys Inc Stock Price, News & Analysis

LEO Pharma and Veeva Systems have announced a strategic partnership aimed at enhancing clinical trials through a patient-centric, paperless approach. LEO Pharma will standardize its operations using Veeva's Clinical Operations Suite, including various integrated clinical products. Key benefits expected include a 25% reduction in clinical trial costs and duration, while improving patient experience and data accuracy. This collaboration aligns with LEO Pharma’s 2030 strategy to expedite innovative treatment delivery.

Veeva Systems (NYSE: VEEV) unveiled the Veeva Vault LIMS, a new cloud application aimed at enhancing quality control lab operations. This addition to the Vault Quality Suite will connect lab functions with the quality ecosystem, streamlining processes for faster batch releases and lower inventory costs. Industry leaders highlight the solution’s potential to improve lab productivity and accelerate testing accuracy. Vault LIMS is scheduled for launch in the second half of 2022.

Veeva Systems (NYSE: VEEV) announced that ConvaTec has chosen Veeva Vault CDMS for electronic data capture in a study focused on detecting wound infections. This proof-of-concept study will evaluate the effectiveness of a combination of biomarkers—wound pH, human neutrophil elastase (HNE), and myeloperoxidase (MPO)—to detect infections. The international study aims to enroll 75 to 90 subjects over approximately 20 weeks. Veeva MedTech supports ConvaTec's efforts with its unified data management solution.

Emmes has partnered with Veeva Systems (NYSE: VEEV) to standardize on Veeva Development Cloud applications, enhancing speed and compliance in clinical research. This collaboration aims to improve operational efficiency across various functional areas, aiding in the growth of Emmes as it expands into new markets. Veeva's cloud solutions will facilitate better collaboration with sponsors and regulatory compliance. Emmes plans to implement several Veeva applications, thereby establishing a unified technology platform for effective clinical and quality management.

Veeva Systems (NYSE: VEEV) announced the launch of Veeva Vault Validation Management, a new application designed to enhance validation lifecycle management for life sciences companies. This solution streamlines validation processes, reduces manual efforts, and supports electronic execution to improve compliance and efficiency. Veeva Vault Validation Management integrates with other Veeva Vault Quality Suite applications, enabling better documentation and data integrity. The application is expected to be available in the second half of 2022, aiming to optimize quality management across the life sciences value chain.

Veeva Systems (NYSE: VEEV) announced the 2021 Veeva R&D and Quality Summit Connect, featuring keynote speakers from Bristol Myers Squibb, GSK, and Roche. This online event on October 14, 2021, aims to enhance knowledge sharing in life sciences, with over 75 sessions focusing on advancements in digital trials. Industry leaders will discuss operational improvements and compliance strategies. Veeva emphasizes its commitment to innovation and customer success, serving over 1,100 clients.

Veeva Systems (NYSE: VEEV) has announced its 2021 Quality & Regulatory Global Summit, set to begin on October 18, 2021. The virtual summit will feature over 15 sessions with industry leaders from companies like Unilever, BASF, and Estée Lauder. Discussions will focus on modernizing business initiatives including product compliance and sustainability. The event is complimentary for Veeva customers and qualified industry professionals. Veeva, known for its cloud software solutions, aims to support industries like consumer goods and chemicals in overcoming regulatory challenges.

Veeva Systems reported a strong second quarter for fiscal 2022, with total revenues of $455.6 million, marking a 29% year-over-year increase. Subscription services revenues also rose to $366.4 million, up 29%. Operating income was $124.6 million, a 38% increase compared to the prior year. Non-GAAP net income increased by 31% to $152.7 million, with diluted net income per share at $0.67. Veeva's outlook for the third quarter projects revenues between $464 and $466 million and for the fiscal year, between $1,830 and $1,835 million.

Veeva Systems (NYSE: VEEV) announces that B. Braun SE has adopted the Veeva Vault Clinical Operations Suite to enhance clinical study management and payments to partner sites globally. This collaboration aims to improve efficiency and oversight in clinical trials, allowing B. Braun to conduct more studies at a faster pace. The integration includes Veeva's solutions for study management and payments, aiding compliance and reducing administrative burdens. The partnership signifies a step in B. Braun's digital transformation and commitment to advancing healthcare.